- Home
- Publications
- Publication Search
- Publication Details
Title
Dapagliflozin
Authors
Keywords
-
Journal
DRUGS
Volume 72, Issue 17, Pages 2289-2312
Publisher
Springer Nature
Online
2012-11-27
DOI
10.2165/11209910-000000000-00000
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin
- (2013) John P.H. Wilding ANNALS OF INTERNAL MEDICINE
- Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or Digoxin
- (2012) Sreeneeranj Kasichayanula et al. ADVANCES IN THERAPY
- Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
- (2012) J. Rosenstock et al. DIABETES CARE
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETES CARE
- Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin
- (2012) Ö. Ljunggren et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range
- (2012) C. J. Bailey et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial
- (2012) R. R. Henry et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Influence of Hepatic Impairment on the Pharmacokinetics and Safety Profile of Dapagliflozin: An Open-Label, Parallel-Group, Single-Dose Study
- (2011) Sreeneeranj Kasichayanula et al. CLINICAL THERAPEUTICS
- Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial
- (2011) M. A. Nauck et al. DIABETES CARE
- Standards of Medical Care in Diabetes--2012
- (2011) DIABETES CARE
- Diagnosis and Classification of Diabetes Mellitus
- (2011) DIABETES CARE
- Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects
- (2011) S. Kasichayanula et al. DIABETES OBESITY & METABOLISM
- Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus
- (2011) S. Kasichayanula et al. DIABETES OBESITY & METABOLISM
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial
- (2011) K. Strojek et al. DIABETES OBESITY & METABOLISM
- Addition of Atrasentan to Renin-Angiotensin System Blockade Reduces Albuminuria in Diabetic Nephropathy
- (2011) D. E. Kohan et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Management of type 2 diabetes: new and future developments in treatment
- (2011) Abd A Tahrani et al. LANCET
- Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study
- (2011) Glenn F. Carlson et al. Diabetes Therapy
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
- (2010) E. Ferrannini et al. DIABETES CARE
- Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects
- (2010) S. Kasichayanula et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight
- (2010) L. Zhang et al. DIABETES OBESITY & METABOLISM
- Sodium-Glucose Co-Transport Inhibitors
- (2010) Joshua J. Neumiller et al. DRUGS
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment
- (2009) J. P.H. Wilding et al. DIABETES CARE
- Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug
- (2009) Iskandar Idris et al. DIABETES OBESITY & METABOLISM
- Mortality attributable to diabetes: Estimates for the year 2010
- (2009) Gojka Roglic et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Global estimates of the prevalence of diabetes for 2010 and 2030
- (2009) J.E. Shaw et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans
- (2009) M. Obermeier et al. DRUG METABOLISM AND DISPOSITION
- Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus
- (2009) Sunil Nair et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications
- (2009) George L. Bakris et al. KIDNEY INTERNATIONAL
- Prevalence, Treatment, and Control of Diagnosed Diabetes in the U.S. National Health and Nutrition Examination Survey 1999–2004
- (2008) Kwok Leung Ong et al. ANNALS OF EPIDEMIOLOGY
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
- (2008) J. F. List et al. DIABETES CARE
- Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
- (2008) Wei Meng et al. JOURNAL OF MEDICINAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More